Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.

BACKGROUND Identifying molecular markers for tumor recurrence is critical in successfully selecting patients with stage III colon cancer who are more likely to benefit from adjuvant chemotherapy. The present study analyzed a subset of 10 polymorphisms within eight genes involved in the tumor angiogenesis pathway and their impact on prognosis in stage III colon cancer patients treated with adjuvant chemotherapy. PATIENTS AND METHODS Blood samples were obtained from 125 patients with locally advanced colon cancer at University of Southern California medical facilities. DNA was extracted from peripheral blood and the genotypes were analyzed using PCR-restriction fragment length polymorphism and 5'-end [gamma-(33)P] ATP-labeled PCR protocols. RESULTS Polymorphisms in vascular endothelial growth factor (VEGF) (C+936T; P = 0.003, log-rank test) and interleukin-8 (IL-8) (T-251A; P = 0.04, log-rank test) were independently associated with risk of recurrence in stage III colon cancer patients. In combined analysis, grouping alleles into favorable versus nonfavorable alleles, high expression variants of VEGF C+936T and IL-8 T-251A were associated with a higher likelihood of developing tumor recurrence (P < 0.001). CONCLUSION High expression variants of VEGF C+936T and IL-8 T-251A were associated with shorter time to tumor recurrence, indicating that the analysis of angiogenesis-related gene polymorphisms may help to identify patient subgroups at high risk for tumor recurrence.

[1]  Y. Hirooka,et al.  Interleukin-8 Promoter Polymorphism Increases the Risk of Atrophic Gastritis and Gastric Cancer in Japan , 2005, Cancer Epidemiology Biomarkers & Prevention.

[2]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[5]  R. Strieter.  Masters of angiogenesis , 2005, Nature Medicine.

[6]  L. Ellis,et al.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. , 1997, Archives of surgery.

[7]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[8]  D. Kwiatkowski,et al.  Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families , 2000, Thorax.

[9]  B. Paulweber,et al.  A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk , 2003, International journal of cancer.

[10]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[11]  T. Koike,et al.  The polymorphism interleukin 8 −251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population , 2005, Gut.

[12]  C. C. Chen,et al.  The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. , 1985, Statistics in medicine.

[13]  Sander Greenland,et al.  Modern Epidemiology 3rd edition , 1986 .

[14]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Yuan,et al.  Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. , 2000, American journal of respiratory and critical care medicine.

[16]  Takashi Ueda,et al.  Serum levels of cytokines in patients with colorectal cancer: Possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis , 1994, Journal of Gastroenterology.

[17]  S. Groshen,et al.  Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. , 2005, Clinical colorectal cancer.

[18]  J. Park,et al.  Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Primary Lung Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[19]  N. Akar,et al.  Vascular endothelial growth factor 936 C/T polymorphism in cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[21]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[22]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[23]  P C Albertsen,et al.  Expression of vascular endothelial growth factor receptors in human prostate cancer. , 1999, Urology.

[24]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[25]  D. Hinton,et al.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. , 2001, Blood.

[26]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[27]  R. Salgia,et al.  Chemokine Receptors CXCR-1/2 Activate Mitogen-activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells* , 2000, The Journal of Biological Chemistry.

[28]  M. Burdick,et al.  Cancer CXC chemokine networks and tumour angiogenesis. , 2006, European journal of cancer.

[29]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[30]  J. Y. Park,et al.  Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  A. Medford,et al.  Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome , 2005, Thorax.

[32]  Michelle L. Varney,et al.  IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis1 , 2003, The Journal of Immunology.

[33]  Yi-ping Lin,et al.  The −251T Allele of the Interleukin-8 Promoter Is Associated with Increased Risk of Gastric Carcinoma Featuring Diffuse-Type Histopathology in Chinese Population , 2005, Clinical Cancer Research.

[34]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[35]  S. Ahmed,et al.  Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. , 2006, Human immunology.

[36]  S. Groshen,et al.  Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. , 2006, Pharmacogenomics.